Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
O15514
UPID:
RPB4_HUMAN
Alternative names:
DNA-directed RNA polymerase II subunit D; RNA polymerase II 16 kDa subunit
Alternative UPACC:
O15514; Q52LT4
Background:
DNA-directed RNA polymerase II subunit RPB4, also known as DNA-directed RNA polymerase II subunit D, plays a pivotal role in the transcription of DNA into RNA, utilizing ribonucleoside triphosphates as substrates. It is a crucial component of RNA polymerase II, responsible for synthesizing mRNA precursors and various functional non-coding RNAs. The RPB4 subunit, in conjunction with RPB7, forms a subcomplex that significantly influences the transcription machinery's structure and function.
Therapeutic significance:
Understanding the role of DNA-directed RNA polymerase II subunit RPB4 could open doors to potential therapeutic strategies.